{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:49:06Z","timestamp":1701996546333},"reference-count":0,"publisher":"Frontline Medical Communications, Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.12788\/cutis.0899","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T17:06:01Z","timestamp":1701968761000},"source":"Crossref","is-referenced-by-count":0,"title":["Dupilumab for Dyshidrotic Eczema With Secondary Improvement in Eosinophilic Interstitial Lung Disease"],"prefix":"10.12788","volume":"112","author":[{"given":"Nicole J","family":"Levin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","container-title":["Cutis"],"original-title":[],"link":[{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/CT112005016_e.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T17:06:02Z","timestamp":1701968762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdedge.com\/dermatology\/article\/266608\/atopic-dermatitis\/dupilumab-dyshidrotic-eczema-secondary-improvement"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.12788\/cutis.0899","relation":{},"subject":[],"published":{"date-parts":[[2023,11]]}}}